Yousif Capital Management LLC Reduces Position in Halozyme Therapeutics, Inc. $HALO

Yousif Capital Management LLC reduced its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 20.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 32,047 shares of the biopharmaceutical company’s stock after selling 8,029 shares during the period. Yousif Capital Management LLC’s holdings in Halozyme Therapeutics were worth $2,350,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of HALO. Newbridge Financial Services Group Inc. purchased a new stake in Halozyme Therapeutics during the 2nd quarter valued at about $32,000. Employees Retirement System of Texas acquired a new position in shares of Halozyme Therapeutics during the 2nd quarter worth approximately $34,000. Asset Management One Co. Ltd. purchased a new stake in shares of Halozyme Therapeutics in the second quarter valued at approximately $98,000. EverSource Wealth Advisors LLC increased its holdings in shares of Halozyme Therapeutics by 6.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock valued at $140,000 after purchasing an additional 174 shares during the last quarter. Finally, ST Germain D J Co. Inc. purchased a new position in Halozyme Therapeutics during the second quarter worth approximately $142,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, COO Cortney Caudill sold 4,263 shares of Halozyme Therapeutics stock in a transaction that occurred on Saturday, November 1st. The shares were sold at an average price of $65.19, for a total value of $277,904.97. Following the completion of the sale, the chief operating officer owned 12,737 shares in the company, valued at approximately $830,325.03. This trade represents a 25.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bernadette Connaughton sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $68.48, for a total value of $136,960.00. Following the completion of the sale, the director directly owned 42,952 shares in the company, valued at approximately $2,941,352.96. The trade was a 4.45% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 85,661 shares of company stock valued at $6,036,837. Company insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Stock Up 0.7%

Shares of NASDAQ:HALO opened at $68.87 on Friday. The business has a 50-day moving average price of $67.34 and a 200 day moving average price of $65.49. The company has a current ratio of 1.59, a quick ratio of 1.37 and a debt-to-equity ratio of 1.59. The company has a market capitalization of $8.10 billion, a price-to-earnings ratio of 14.50, a PEG ratio of 0.37 and a beta of 0.95. Halozyme Therapeutics, Inc. has a 12-month low of $47.50 and a 12-month high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 EPS for the quarter, beating analysts’ consensus estimates of $1.63 by $0.09. Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. The company had revenue of $354.26 million for the quarter, compared to analysts’ expectations of $339.18 million. During the same quarter in the prior year, the company posted $1.27 earnings per share. Halozyme Therapeutics’s revenue for the quarter was up 22.1% compared to the same quarter last year. Sell-side analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Wall Street Analysts Forecast Growth

HALO has been the subject of several analyst reports. Morgan Stanley dropped their target price on Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating for the company in a report on Monday, October 20th. Weiss Ratings reissued a “hold (c+)” rating on shares of Halozyme Therapeutics in a research report on Monday, December 22nd. Leerink Partnrs raised shares of Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 14th. JPMorgan Chase & Co. raised their price objective on shares of Halozyme Therapeutics from $63.00 to $65.00 and gave the stock a “neutral” rating in a research report on Monday, October 27th. Finally, Citizens Jmp boosted their target price on shares of Halozyme Therapeutics from $91.00 to $92.00 and gave the company a “market outperform” rating in a report on Tuesday, November 4th. Six analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $75.10.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.